Herbst Tackles Key Questions in Emerging PD-1/PD-L1 Immunotherapy for NSCLC
August 2nd 2014
Emerging agents and pressing research questions in immunotherapy were reviewed in depth during the 15th Annual International Lung Cancer Congress, with Roy S. Herbst, MD, PhD, of the Yale Cancer Center, leading the way.